New Ray Medicine International Holding Limited announced that on April 30, 2021, Mr. Liu Yang tendered his resignation as an executive Director and the chairman of the Board which will take effect on May 15, 2021 as he plans to devote more attention and time to his own business engagement. Upon his resignation which will become effective on May 15, 2021, Mr. Liu will also cease to be the chairman of the corporate governance committee of the Board; a member of the remuneration committee and the nomination committee of the Board; and an authorised representative of the company. The Board further announced that following Mr. Liu's resignation, Ms. Wang Qiuqin, an executive Director and the chief executive officer of the company will be appointed as the Chairman, the chairman of the Corporate Governance Committee and an Authorised Representative in place of Mr. Liu with effect from May 15, 2021. Ms. Wang, aged 43, has been an executive Director of the Board since June 27, 2018 and the Chief Executive Officer since July 31, 2020. She is also a member of the Corporate Governance Committee and a director of a number of subsidiaries of the company as at the date of this announcement. Following the resignation of Mr. Liu as executive Director which will take effect on May 15, 2021: the Remuneration Committee will be reconstituted to comprise Mr. Leung Chi Kin as the chairman and Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny as members; the Nomination Committee will be reconstituted to comprise Mr. Leung as the chairman and Ms. Li and Mr. Sy as members; and the Corporate Governance Committee will be reconstituted to comprise Ms. Wang as the chairman and Mr. Huo Zhihong and Mr. Sy as members.